Exact Sciences cancer test meets goal, but disappoints investors

Thu Apr 18, 2013 7:52am EDT

Related Topics

(Reuters) - Exact Sciences Corp said its molecular screening test for colorectal cancer met a late-stage trial goal of detecting the disease in more patients than other commonly used tests, but shares fell 28 percent as the results were not as robust as some were expecting.

Exact's test, which identifies abnormal DNA in cells shed in a patient's stool, detected 92 percent of colorectal cancers and 42 percent of pre-cancerous polyps in a large late-stage study.

"Pre-cancerous sensitivity, which was the key metric investors were looking at, was well below expectations," Wedbush Securities analyst Zarak Khurshid said, adding that "lower pre-cancer sensitivity may limit the eventual addressable opportunity for the test."

Khurshid was expecting a 55 percent detection rate for pre-cancerous polyps.

Exact's non-invasive test was developed to be a more accurate alternative to currently available non-invasive screenings.

The study compared the performance of its Cologuard test to colonoscopy and fecal immunochemical testing that looks for blood in a stool sample.

While a colonoscopy is considered the most accurate method of detecting colon cancer and polyps, many people avoid the recommended test as it involves inserting a flexible tube into the colon.

The trial was conducted on 10,000 patients between the ages of 50 and 84 years, who were at average risk for colorectal cancer.

Madison, Wisconsin-based Exact Sciences plans to submit the study data to the U.S. Food and Drug Administration as part of its approval application.

Colorectal cancer is the third most commonly diagnosed cancer in the United States, responsible for about 50,000 deaths a year.

The company's shares were down 28 percent to $7.16 before the bell. They closed at $9.97 on Wednesday on the Nasdaq.

(Reporting by Esha Dey in Bangalore, Additional reporting by Susan Kelly in Chicago; Editing by Roshni Menon)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
SeniorMoment wrote:
Colonoscopies are not that bad, since the person is sedated or at some clinic under the control of an anesthesiologist, so the body naturally relaxes. It is however very desirable to have a non-invasive test for colon cancer because a tiny number of colonoscopies will punch a hole in the colon, which may require abdominal surgery to fix, besides sheer cost considerations. 1 in 10,000 or greater times a general anesthetic if used will also result in something more serious, death.

Apr 18, 2013 8:42am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.